ERBB2 and neoplasm: This showed higher age, neoadjuvant therapy, higher pT-, higher pN-stages, vascular invasion, tumor grade, regression, HER2/neu positivity as well as positive JUNB staining significantly correlated to poor overall survival (Table 2).